The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
Open accessAbstract
In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity. This type of inhibition can cause interactions with drugs such as omeprazole, paroxetine, macrolide antibiotics, or mirabegron. A good understanding of mechanism-based inhibition and proper clinical management is needed by clinicians when such drugs are prescribed. It is important to recognize mechanism-based inhibition since it cannot be prevented by separating the time of administration of the interacting drugs. Here, we provide a comprehensive overview of the different types of mechanism-based inhibition, along with illustrative examples of how mechanism-based inhibition might affect prescribing and clinical behaviors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clopidogrel with or without Omeprazole in Coronary Artery Disease
Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., Shook, T. L., Lapuerta, P., Goldsmith, M. A., Laine, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007964 · Cited by 1,240
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
Gilard, M., Arnaud, B., Cornily, J.-C., Le Gal, G., Lacut, K., Le Calvez, G., Mansourati, J., Mottier, D., Abgrall, J.-F., & Boschat, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.064 · Cited by 1,015
Ho, P. M. (2009) · JAMA · doi:10.1001/jama.2009.261 · Cited by 1,007
(2007) · PubMed · Cited by 953
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
Juurlink, D. N., Gomes, T., Ko, D. T., Szmitko, P. E., Austin, P. C., Tu, J. V., Henry, D. A., Kopp, A., & Mamdani, M. M. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.082001 · Cited by 766
The challenge of managing drug interactions in elderly people
Mallet, L., Spinewine, A., & Huang, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61092-7 · Cited by 537
Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Gemfibrozil greatly increases plasma concentrations of cerivastatin
Backman, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 336
Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P., & Parkinson, A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007633 · Cited by 330
Niemi, M., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1034-7 · Cited by 284
Bertelsen, K. M., Venkatakrishnan, K., von Moltke, L. L., Obach, R. S., & Greenblatt, D. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.3.289 · Cited by 276
Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors: A Cohort Study
Ray, W. A., Murray, K. T., Griffin, M. R., Chung, C. P., Smalley, W. E., Hall, K., Daugherty, J. R., Kaltenbach, L. A., & Stein, C. M. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-6-201003160-00003 · Cited by 230
Doan, J., Zakrzewski-Jakubiak, H., Roy, J., Turgeon, J., & Tannenbaum, C. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r621 · Cited by 189
Self-citationDrolet, B., Khalifa, M., Daleau, P., Hamelin, B. A., & Turgeon, J. (1998) · Circulation · doi:10.1161/01.cir.97.2.204 · Cited by 157
Self-citationFrelinger, A. L., Lee, R. D., Mulford, D. J., Wu, J., Nudurupati, S. V., Nigam, A., Brooks, J. K., Bhatt, D. L., & Michelson, A. D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.024 · Cited by 151
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen, X., Wang, J. S., Backman, J. T., Kivistö, K. T., & Neuvonen, P. J. (2001) · PubMed · Cited by 139
Vickers, A. E. M., Sinclair, J. R., Zollinger, M., Heitz, F., Glänzel, U., Johanson, L., & Fischer, V. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15022-2 · Cited by 120
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone
Jaakkola, T., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.12.266 · Cited by 119
Karaźniewicz‐Łada, M., Danielak, D., Burchardt, P., Kruszyna, Ł., Komosa, A., Lesiak, M., & Główka, F. K. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0105-2 · Cited by 100
Laine, K., Tybring, G., Härtter, S., et al. (2001) · PubMed · Cited by 89
Investigation of terbinafine as a CYP2D6 inhibitor in vivo
ABDELRAHMAN, S., Gotschall, R. R., KAUFFMAN, R., Leeder, J. S., & KEARNS, G. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70065-2 · Cited by 86
Sherwood, M. W., Melloni, C., Jones, W. S., Washam, J. B., Hasselblad, V., & Dolor, R. J. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002245 · Cited by 83
Bundhun, P. K., Teeluck, A. R., Bhurtu, A., & Huang, W.-Q. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0453-6 · Cited by 77
Varma, M. V. S., Lin, J., Bi, Y., Kimoto, E., & Rodrigues, A. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.064303 · Cited by 69
Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug–Drug Interactions
Storelli, F., Matthey, A., Lenglet, S., Thomas, A., Desmeules, J. A., & Daali, Y. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.889 · Cited by 66
Structural and functional effects of cytochrome b5 interactions with human cytochrome P450 enzymes
Bart, A. G., & Scott, E. E. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000220 · Cited by 61
Uttamsingh, V., Gallegos, R., Liu, J. F., Harbeson, S. L., Bridson, G. W., Cheng, C., Wells, D. S., Graham, P. B., Zelle, R. E., & Tung, R. D. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.223768 · Cited by 59
Effect of the Treatment Period With Erythromycin on Cytochrome P450 3A Activity in Humans
Okudaira, T., Kotegawa, T., Imai, H., Tsutsumi, K., Nakano, S., & Ohashi, K. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007302562 · Cited by 54
Vaduganathan, M., Cannon, C. P., Cryer, B., Liu, Y., Hsieh, W.-H., Doros, G. D., Cohen, M. C., Lanas, Á., Schnitzer, T. J., Shook, T., et al. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.03.042 · Cited by 53
Bhurke, S., Martin, B. C., Li, C., Franks, A. M., Bursac, Z., & Said, Q. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01112.x · Cited by 47
Lilja, J. J., Backman, J. T., & Neuvonen, P. J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02323.x · Cited by 45
Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro
Rasmussen, B. B., Nielsen, T. L., & Brøsen, K. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050544 · Cited by 45
Zhang, H., Gao, N., Liu, T., Fang, Y., Qi, B., Wen, Q., Zhou, J., Jia, L.-J., & Qiao, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128547 · Cited by 36
Lin, C., Shen, L., Wu, F. L., Bai, C., & Gau, C. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04250.x · Cited by 26
Furtado, R. H. D. M., Giugliano, R. P., Strunz, C. M. C., Filho, C. C., Ramires, J. A. F., Filho, R. K., Lemos, P. A., Pereira, A. C., Rocha, T. R., Freire, B. T., et al. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0172-5 · Cited by 26
Genotype‐sensitive reversible and time‐dependent CYP 2D6 inhibition in human liver microsomes
Storelli, F., Desmeules, J. A., & Daali, Y. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13124 · Cited by 14
O’Donnell, L. K., Chen, T. F., Gnjidic, D., & Hilmer, S. N. (2016) · American Journal of Pharmaceutical Education · doi:10.5688/ajpe80463 · Cited by 12
Ogilvie, B. W. (2015) · KU ScholarWorks (The University of Kansas) · Cited by 2
Cited by
Coloring Molecules with Explainable Artificial Intelligence for Preclinical Relevance Assessment
Jiménez-Luna, J., Skalic, M., Weskamp, N., & Schneider, G. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01344 · Cited by 96
Shaheen, K., Alam, A., Elhenawy, A. A., Khan, I. A., Rahman, F. U., Ali, A., Rehman, M. U., AlAsmari, A. F., Alasmari, F., Ahmad, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-13351-2 · Cited by 10
Metadata
- Authors
- Deodhar, M., Al Rihani, S. B., Arwood, M. J., Darakjian, L., Dow, P., Turgeon, J., & Michaud, V.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2020-09-04
- Volume
- 12
- Issue
- 9
- Pages
- 846
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3083556913
- Cited by
- 261
- References
- 38
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.